{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:52:10Z","timestamp":1695538330531},"reference-count":17,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1507\/endocrj.ej14-0610","type":"journal-article","created":{"date-parts":[[2015,2,23]],"date-time":"2015-02-23T19:14:39Z","timestamp":1424718879000},"page":"411-416","source":"Crossref","is-referenced-by-count":3,"title":["Effects of rapid-acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes"],"prefix":"10.1507","volume":"62","author":[{"given":"Nagaaki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Diabetes, Osaka City Juso Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Hiura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Osaka City Juso Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. American Diabetes Association (2014) Standards of medical care in diabetes&mdash;2014. <i>Diabetes Care<\/i> 37 Suppl 1: S14-S80.","DOI":"10.2337\/dc14-S014"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff Jr. DC, Bigger JT, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. <i>N Engl J Med<\/i> 358: 2545-2559.","DOI":"10.1056\/NEJMoa0802743"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, et al. (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. <i>Diabetes Care<\/i> 33: 983-990.","DOI":"10.2337\/dc09-1278"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, et al. (2010) Severe hypoglycemia and risks of vascular events and death. <i>N Engl J Med<\/i> 363: 1410-1418.","DOI":"10.1056\/NEJMoa1003795"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. <i>N Engl J Med<\/i> 358: 2560-2572.","DOI":"10.1056\/NEJMoa0802987"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, et al. (2012) Increased mortality of patients with diabetes reporting severe hypoglycemia. <i>Diabetes Care<\/i> 35: 1897-1901.","DOI":"10.2337\/dc11-2054"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Becker RH, Frick AD (2008) Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. <i>Clin Pharmacokinet<\/i> 47: 7-20.","DOI":"10.2165\/00003088-200847010-00002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE (2013) Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. <i>Diabetes Care<\/i> 36: 273-275.","DOI":"10.2337\/dc12-0808"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al. (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. <i>J Diabetes Investig<\/i> 1: 212-228.","DOI":"10.1111\/j.2040-1124.2010.00074.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Heise T, Nosek L, Spitzer H, Heinemann L, Niemoller E, et al. (2007) Insulin glulisine: a faster onset of action compared with insulin lispro. <i>Diabetes Obes Metab<\/i> 9: 746-753.","DOI":"10.1111\/j.1463-1326.2007.00746.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR (2008) A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. <i>Diabetes Res Clin Pract<\/i> 79: 269-275.","DOI":"10.1016\/j.diabres.2007.11.013"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bolli GB, Luzio S, Marzotti S, Porcellati F, Sert-Langeron C, et al. (2011) Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 13: 251-257.","DOI":"10.1111\/j.1463-1326.2010.01343.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Arnolds S, Rave K, Hovelmann U, Fischer A, Sert-Langeron C, et al. (2010) Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. <i>Exp Clin Endocrinol Diabetes<\/i> 118: 662-664.","DOI":"10.1055\/s-0030-1252067"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Dailey G, Rosenstock J, Moses RG, Ways K (2004) Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. <i>Diabetes Care<\/i> 27: 2363-2368.","DOI":"10.2337\/diacare.27.10.2363"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ohta A, Arai K, Nishine A, Sada Y, Kato H, et al. (2013) Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine. <i>Endocr J<\/i> 60: 173-177.","DOI":"10.1507\/endocrj.EJ12-0251"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Clauson PG, Linde B (1995) Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. <i>Diabetes Care<\/i> 18: 986-991.","DOI":"10.2337\/diacare.18.7.986"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Maciejczyk M, Wiecek M, Szymura J, Szygula Z, Wiecha S, et al. (2014) The influence of increased body fat or lean body mass on aerobic performance. <i>PLoS One<\/i> 9: e95797.","DOI":"10.1371\/journal.pone.0095797"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T01:13:08Z","timestamp":1566349988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/5\/62_EJ14-0610\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej14-0610","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}